The value of the endomyocardial biopsy in monitoring the cardiac allograft.
This session focusses on pathological classification and diagnosis of ACR and AMR, pitfalls in differentiating rejection from infection, morphological correlates of HLA, non-HLA positive results to tissue findings, comments on the timeframe when cfDNA results reflect histopathological findings and highlights advantages and disadvantages of pathological examination, considering essential contribution of pathology to development of understanding of etiology of rejection as for instance in classification of biopsy negative AMR. Furthermore, the importance of tissue investigation to exclude other pathologies, as TVP, neoplasia, recurrence of autoimmune disorders in form of granulomatous inflammation is being highlighted.
The audience is encouraged to share their experience and perspective, if desired anonymously, yet in an interactive way.
Clinical input will be provided by Prof John Dunning, as required.